Overview MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) Status: Recruiting Trial end date: 2021-12-01 Target enrollment: Participant gender: Summary This is a dose-escalation phase I trial to evaluate the safety and tolerability of MAX-40279 in subjects with acute myelogenous leukemia(AML). Phase: Phase 1 Details Lead Sponsor: Maxinovel Pty., Ltd.